Evaluation of Venetoclax Combined With Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Untreated BCL-2 IHC-Positive DLBCL Patients

The primary objective of this study is to evaluate the **safety**, **efficacy**, and **pharmacokinetics** of Venetoclax in combination with Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in participants with untreated BCL-2 immunohistochemistry-positive **Diffuse Large B-Cell Lymphoma (DLBCL)**. This is clinically relevant as it aims to determine the potential benefits and risks of this combination therapy in improving treatment outcomes for patients with this aggressive form of lymphoma. The study focuses on assessing how well the combination works in reducing tumor size, its impact on patient survival, and the body's processing of the drugs involved.

The clinical trial involves a total of **14 participants** diagnosed with **Diffuse large B-cell lymphoma (DLBCL)**, Grade 3B follicular lymphoma, High grade B-cell lymphoma (HGBL), or Epstein-Barr virus−positive DLBCL. The study population includes both male and female subjects, with an age range that encompasses adults and older adults. Participants were selected based on their diagnosis, and the trial includes a vulnerable population. The selection criteria did not specify any particular lifestyle considerations such as diet or physical activity. The sponsor did not provide detailed information regarding the main objective of the trial or specific inclusion criteria.

The clinical trial is designed to evaluate the **safety**, efficacy, and pharmacokinetics of a combination therapy involving Venetoclax, Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in participants with untreated **Diffuse Large B-Cell Lymphoma (DLBCL)**, Grade 3B follicular lymphoma, high-grade B-cell lymphoma, and Epstein-Barr virus-positive DLBCL. This trial is structured as a Phase 1 study, employing a randomized, double-blind, and controlled methodology to ensure the reliability and validity of the results. The estimated duration of the trial spans from October 11, 2021, to January 18, 2025, allowing for comprehensive data collection and analysis.

Participants will undergo a series of study visits, beginning with an inclusion (screening) visit to assess eligibility based on predefined criteria. Following successful screening, participants will be enrolled and randomized into treatment groups. Throughout the trial, regular follow-up visits will be conducted to monitor the participants' response to the treatment, assess any adverse effects, and ensure adherence to the study protocol. These visits are crucial for collecting data on the primary and secondary endpoints of the study. The trial will conclude with an end-of-study visit, where final assessments will be made to evaluate the overall outcomes of the treatment regimen.

The expected length of participant involvement in the trial is approximately three years, contingent upon individual response and adherence to the study protocol. Conditions that may lead to early termination from the study include significant adverse reactions, non-compliance with study procedures, or withdrawal of consent by the participant. The trial is conducted under strict ethical guidelines, ensuring the safety and well-being of all participants throughout the study duration.

The clinical trial documentation does not provide specific details regarding the **experimental medication** used in the study. Information such as the name, pharmaceutical form, dosage, route, and frequency of administration is not available. Additionally, there is no data on whether the medication is a **paediatric formulation** or if it is classified as an **orphan drug**. The maximum daily dose, total dose, and treatment period are also unspecified.

Details about any **non-experimental treatments** used in the study, such as standard-of-care therapy, placebo, or comparator treatment, are not provided. There is no information on additional relevant aspects of drug administration, dosing schedules, or participant compliance monitoring. The absence of this data limits the ability to describe the treatments comprehensively.

The clinical trial is designed to assess efficacy through a structured evaluation process. The trial is categorized as a Phase 1 study, indicating an initial investigation into the safety and potential efficacy of the intervention. The trial is scheduled to commence recruitment on October 11, 2021, with an estimated completion date of January 18, 2025. Although specific efficacy parameters such as primary and secondary endpoints are not detailed, Phase 1 trials typically focus on safety and dosage, with preliminary efficacy assessments often included. The trial will likely employ standard methodologies for data collection and analysis, consistent with Phase 1 objectives, to ensure the reliability and validity of the findings. The absence of detailed endpoints suggests that the trial may utilize exploratory measures to guide future research phases.